NASDAQ:PCRX - Pacira BioSciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $82.00
  • Forecasted Upside: 33.53 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.17 (-3.41%)

This chart shows the closing price for PCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pacira BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCRX

Analyst Price Target is $82.00
▲ +33.53% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $82.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 33.53% upside from the last price of $61.41.

This chart shows the closing price for PCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Pacira BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2022Northland SecuritiesBoost Price Target$61.00 ➝ $67.00High
2/26/2022WedbushReiterated RatingBuy$97.00 ➝ $94.00Medium
2/25/2022HC WainwrightBoost Price TargetBuy$86.00 ➝ $90.00High
2/16/2022WedbushReiterated RatingBuy$97.00Low
1/19/2022BarclaysBoost Price TargetOverweight$92.00 ➝ $96.00Low
1/7/2022WedbushReiterated RatingBuy$97.00High
1/4/2022Northland SecuritiesBoost Price Target$57.00 ➝ $61.00Medium
1/3/2022JPMorgan Chase & Co.Initiated CoverageOverweight$83.00Medium
11/5/2021BarclaysBoost Price TargetOverweight$91.00 ➝ $92.00High
11/4/2021HC WainwrightBoost Price TargetBuy$80.00 ➝ $86.00Low
10/18/2021Needham & Company LLCBoost Price TargetBuy$80.00 ➝ $84.00Low
10/12/2021HC WainwrightLower Price TargetBuy$84.00 ➝ $80.00Medium
10/12/2021BMO Capital MarketsLower Price TargetMarket Perform$66.00 ➝ $60.00Medium
10/5/2021Northland SecuritiesLower Price TargetMarket Perform$66.00 ➝ $57.00High
10/1/2021BarclaysLower Price TargetOverweight$95.00 ➝ $91.00High
9/22/2021WedbushReiterated RatingBuy$93.00Low
8/4/2021HC WainwrightLower Price TargetBuy$86.00 ➝ $84.00Medium
7/26/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$70.00 ➝ $75.00Low
7/14/2021HC WainwrightReiterated RatingBuy$86.00Low
5/10/2021BMO Capital MarketsLower Price TargetMarket Perform$72.00 ➝ $70.00Medium
5/5/2021Northland SecuritiesLower Price TargetMarket Perform$75.00 ➝ $66.00Low
4/9/2021Berenberg BankInitiated CoverageBuy$93.00Low
3/1/2021HC WainwrightBoost Price TargetBuy$70.00 ➝ $86.00Low
2/26/2021BarclaysBoost Price TargetOverweight$79.00 ➝ $94.00Medium
2/11/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$72.00 ➝ $75.00Low
1/25/2021Northland SecuritiesBoost Price TargetOutperform$67.00 ➝ $72.00Medium
1/21/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$63.00 ➝ $75.00High
1/20/2021Piper SandlerBoost Price TargetOverweight$65.00 ➝ $90.00Low
1/8/2021Needham & Company LLCBoost Price TargetBuy$67.00 ➝ $76.00High
1/6/2021Royal Bank of CanadaBoost Price TargetOutperform$65.00 ➝ $70.00N/A
12/14/2020BarclaysBoost Price TargetOverweight$73.00 ➝ $79.00Low
12/9/2020Needham & Company LLCLower Price TargetBuy$68.00 ➝ $67.00High
11/2/2020WedbushLower Price TargetOutperform$85.00 ➝ $83.00Low
10/7/2020WedbushReiterated RatingBuy$85.00Medium
9/30/2020Jefferies Financial GroupBoost Price Target$69.00 ➝ $75.00Low
9/21/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$58.00 ➝ $67.00Medium
9/9/2020Needham & Company LLCBoost Price TargetBuy$64.00 ➝ $68.00High
8/17/2020WedbushReiterated RatingBuy$85.00Medium
8/14/2020Truist FinancialBoost Price Target$54.00 ➝ $65.00Low
8/10/2020HC WainwrightBoost Price TargetBuy$68.00 ➝ $70.00High
7/20/2020WedbushReiterated RatingBuy$85.00Low
7/13/2020HC WainwrightReiterated RatingBuy$63.00 ➝ $68.00High
7/10/2020Jefferies Financial GroupBoost Price TargetBuy$53.00 ➝ $69.00Low
7/6/2020Needham & Company LLCBoost Price TargetBuy$52.00 ➝ $64.00Medium
7/6/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$49.00 ➝ $65.00Medium
7/2/2020WedbushReiterated RatingBuy$85.00N/A
7/1/2020Royal Bank of CanadaBoost Price TargetOutperform$56.00 ➝ $62.00High
6/30/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $58.00Medium
6/30/2020Northland SecuritiesBoost Price TargetMarket Perform$50.00 ➝ $54.00Low
5/27/2020Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
5/26/2020GuggenheimInitiated CoverageNeutralLow
5/13/2020Royal Bank of CanadaReiterated RatingBuy$56.00High
5/12/2020WedbushReiterated RatingBuy$85.00High
5/8/2020SVB LeerinkBoost Price TargetBuy$44.00 ➝ $45.00Medium
5/7/2020Stifel NicolausLower Price TargetHold$49.00 ➝ $48.00Low
4/30/2020Needham & Company LLCLower Price TargetBuy$56.00 ➝ $52.00High
4/27/2020WedbushReiterated RatingBuy$85.00Medium
4/17/2020Northland SecuritiesReiterated RatingBuy$50.00High
4/7/2020Northland SecuritiesInitiated CoverageOutperform$50.00High
3/23/2020Piper SandlerLower Price Target$60.00 ➝ $49.00High
3/23/2020Royal Bank of CanadaLower Price TargetOutperform$65.00 ➝ $56.00High
3/20/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$46.00 ➝ $44.00High
2/24/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $63.00Medium
2/20/2020WedbushReiterated RatingBuy$85.00N/A
2/20/2020Stifel NicolausReiterated RatingHold$49.00High
2/20/2020Piper SandlerBoost Price TargetBuy$54.00 ➝ $60.00Low
1/23/2020SunTrust BanksInitiated CoverageBuy$60.00Low
1/7/2020WedbushReiterated RatingBuy$85.00Low
12/18/2019Royal Bank of CanadaReiterated RatingBuyLow
12/17/2019WedbushReiterated RatingBuy$85.00Medium
11/8/2019BarclaysBoost Price TargetOverweight$52.00 ➝ $55.00Medium
11/7/2019Needham & Company LLCReiterated RatingBuy$56.00High
11/7/2019CowenReiterated RatingHold$41.00High
11/6/2019BTIG ResearchInitiated CoverageBuy$56.00 ➝ $56.00Medium
10/8/2019Jefferies Financial GroupSet Price TargetBuy$60.00Low
8/9/2019Stifel NicolausSet Price TargetHold$42.00Low
8/9/2019BMO Capital MarketsLower Price TargetMarket Perform$46.00 ➝ $43.00Low
6/28/2019WedbushSet Price TargetBuy$85.00Medium
6/12/2019WedbushReiterated RatingOutperform$85.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$52.00Low
5/6/2019MizuhoUpgradeUnderperform ➝ Neutral$29.00 ➝ $38.00Low
5/3/2019BMO Capital MarketsSet Price TargetHold$46.00Low
5/2/2019Stifel NicolausUpgradeSell ➝ Hold$45.00Low
4/9/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00Low
3/8/2019WedbushReiterated RatingOutperform$85.00Low
3/8/2019Stifel NicolausReiterated RatingPositive ➝ Sell$33.00Low
3/1/2019BMO Capital MarketsSet Price TargetHold$44.00Medium
3/1/2019CowenReiterated RatingHoldLow
2/12/2019National SecuritiesInitiated CoverageSellMedium
2/1/2019MizuhoDowngradeNeutral ➝ UnderperformHigh
1/29/2019WedbushSet Price TargetBuy$91.00High
11/5/2018WedbushSet Price TargetBuy$85.00 ➝ $90.00Low
11/5/2018MizuhoBoost Price TargetNeutral$46.00Medium
11/2/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$45.00 ➝ $50.00Low
11/2/2018Jefferies Financial GroupBoost Price TargetBuy$60.00Low
11/2/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$40.00 ➝ $47.00Low
11/2/2018Royal Bank of CanadaSet Price TargetBuy$60.00High
11/2/2018HC WainwrightBoost Price TargetBuy$60.00High
11/1/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Buy$56.00 ➝ $63.00High
11/1/2018Needham & Company LLCSet Price TargetBuy$60.00High
11/1/2018Piper Jaffray CompaniesSet Price TargetBuy$55.00High
11/1/2018MizuhoReiterated RatingHold$43.00High
10/10/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $48.00High
10/9/2018Piper Jaffray CompaniesReiterated RatingBuy$51.00High
9/19/2018Royal Bank of CanadaSet Price TargetBuy$55.00High
9/13/2018Stifel NicolausInitiated CoverageSell$41.00Low
8/6/2018BarclaysBoost Price TargetOverweight ➝ Buy$40.00 ➝ $50.00Low
8/6/2018WedbushReiterated RatingOutperform$85.00 ➝ $80.00Low
8/6/2018WedbushSet Price TargetOutperform ➝ Outperform$85.00Low
8/6/2018Bank of AmericaDowngradeBuy ➝ NeutralLow
8/3/2018Needham & Company LLCUpgradeHold ➝ Buy$54.00High
8/3/2018HC WainwrightReiterated RatingBuy$52.00High
8/2/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00High
8/2/2018Royal Bank of CanadaSet Price TargetBuy$50.00High
8/2/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Neutral$40.00High
7/26/2018HC WainwrightSet Price TargetBuy$48.00High
7/10/2018CowenReiterated RatingHoldMedium
7/10/2018HC WainwrightReiterated RatingBuy$48.00Medium
6/29/2018MizuhoReiterated RatingHold$31.00Low
5/17/2018OppenheimerReiterated RatingHoldLow
5/4/2018JMP SecuritiesSet Price TargetOutperform ➝ Buy$65.00 ➝ $56.00Medium
5/3/2018MizuhoReiterated RatingHold$31.00Medium
5/3/2018HC WainwrightSet Price TargetBuy$48.00Low
4/30/2018WedbushReiterated RatingOutperform$80.00Medium
4/10/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$40.00 ➝ $43.00Low
4/9/2018WedbushLower Price TargetOutperform$72.00 ➝ $80.00High
4/9/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$31.00 ➝ $34.00Low
4/9/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Hold$40.00 ➝ $43.00Low
4/9/2018HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $48.00Medium
4/9/2018Piper Jaffray CompaniesSet Price TargetBuy$44.00Medium
3/21/2018MizuhoLower Price TargetNeutral ➝ Neutral$44.00 ➝ $31.00High
3/1/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$32.00 ➝ $31.00Medium
3/1/2018Royal Bank of CanadaSet Price TargetBuy$44.00High
3/1/2018HC WainwrightSet Price TargetBuy$45.00High
3/1/2018OppenheimerReiterated RatingHoldHigh
2/16/2018Needham & Company LLCDowngradeBuy ➝ Hold$55.00High
2/16/2018BarclaysReiterated RatingBuy$40.00High
2/15/2018BMO Capital MarketsLower Price TargetMarket Perform$41.00 ➝ $32.00High
2/15/2018OppenheimerReiterated RatingHoldHigh
2/13/2018Piper Jaffray CompaniesSet Price TargetBuy$49.00Low
1/5/2018WedbushReiterated RatingBuyLow
1/4/2018HC WainwrightSet Price TargetBuy ➝ Buy$52.00 ➝ $55.00Low
1/4/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
1/4/2018Royal Bank of CanadaSet Price TargetBuy$54.00High
1/2/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$46.00Low
12/20/2017WedbushReiterated RatingBuy$80.00Low
12/18/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$47.00High
11/29/2017MizuhoDowngradeBuy ➝ Neutral$53.00 ➝ $44.00Medium
11/20/2017WedbushReiterated RatingBuy$80.00N/A
11/16/2017Janney Montgomery ScottSet Price TargetSell$27.00N/A
11/9/2017OppenheimerReiterated RatingHoldN/A
11/9/2017HC WainwrightReiterated RatingBuy ➝ Buy$52.00N/A
11/9/2017Jefferies Financial GroupLower Price TargetBuy$52.00N/A
11/8/2017BMO Capital MarketsBoost Price TargetMarket Perform$38.00 ➝ $39.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$55.00N/A
10/26/2017Janney Montgomery ScottDowngradeNeutral ➝ Sell$27.00N/A
10/25/2017WedbushReiterated RatingOutperform$87.00N/A
10/19/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$55.00 ➝ $52.00N/A
10/13/2017Royal Bank of CanadaReiterated RatingBuy$54.00N/A
10/4/2017Bank of AmericaLower Price TargetBuy$46.00 ➝ $45.00Low
9/28/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$41.00Medium
9/26/2017Needham & Company LLCReiterated RatingBuyLow
9/25/2017MizuhoReiterated RatingBuy$53.00Medium
9/7/2017Jefferies Financial GroupReiterated RatingBuy$59.00Medium
9/7/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLow
9/7/2017OppenheimerInitiated CoverageMarket PerformMedium
9/6/2017UBS GroupInitiated CoverageMarket PerformMedium
9/5/2017Royal Bank of CanadaReiterated RatingOutperform$54.00Medium
8/23/2017WedbushReiterated RatingOutperform$87.00Medium
8/22/2017MizuhoReiterated RatingBuy$54.00 ➝ $53.00Low
8/22/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$55.00Low
8/21/2017Janney Montgomery ScottUpgradeSell ➝ Neutral$31.00Low
8/3/2017BMO Capital MarketsLower Price TargetMarket Perform$42.00 ➝ $40.00Low
8/3/2017HC WainwrightSet Price TargetBuy$59.00Medium
8/2/2017CowenReiterated RatingHoldMedium
7/30/2017Royal Bank of CanadaSet Price TargetBuy$58.00Low
7/26/2017MizuhoReiterated RatingBuy$54.00Medium
7/19/2017WedbushReiterated RatingOutperform$87.00Low
7/14/2017CowenReiterated RatingHoldLow
6/27/2017Royal Bank of CanadaSet Price TargetBuy$58.00N/A
6/21/2017WedbushReiterated RatingOutperform$87.00High
5/24/2017WedbushReiterated RatingOutperform$87.00Low
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Pacira BioSciences logo
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Read More

Today's Range

Now: $61.41
Low: $60.67
High: $63.66

50 Day Range

MA: $72.18
Low: $59.51
High: $81.64

52 Week Range

Now: $61.41
Low: $45.05
High: $82.16


406,147 shs

Average Volume

543,599 shs

Market Capitalization

$2.79 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, BMO Capital Markets, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Northland Securities,, TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for PCRX.

What is the current price target for Pacira BioSciences?

0 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $82.00, suggesting a possible upside of 33.5%.
View the latest price targets for PCRX.

What is the current consensus analyst rating for Pacira BioSciences?

Pacira BioSciences currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCRX will outperform the market and that investors should add to their positions of Pacira BioSciences.
View the latest ratings for PCRX.

How do I contact Pacira BioSciences' investor relations team?

Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is (813) 553-6680 and its investor relations email address is [email protected] The official website for Pacira BioSciences is Learn More about contacing Pacira BioSciences investor relations.